Přejít na obsah
All articles

Endocrinology

Diabetes a Silent Disease

Diabetes in Ireland: Causes, Symptoms, Treatments and the Future of Care — An estimated 308,000 people live with diabetes in Ireland. This guide covers warning signs, today's best treatments (including GLP-1 and SGLT2 therapies), and the breakthroughs on the horizon.

Dr Tiago Miguel FigueiraJuly 18, 202619 min readLast reviewed July 21, 2026
Ireland · Clinical guide

Causes, symptoms, current treatments and the future of diabetes care.

Diabetes is one of the most common chronic conditions in Ireland — and one of the most misunderstood. It is often described as a "silent disease" because Type 2 diabetes, which accounts for approximately 88% of all cases, can develop slowly over many years with few noticeable symptoms. By the time many people are diagnosed, the condition has already been present for some time.

Evidence-basedAligned with HSE guidance

Section 01

Diabetes in Ireland: Understanding the Scale

Ireland does not yet have a national diabetes registry — a gap repeatedly highlighted by Diabetes Ireland and the HSE National Clinical Programme for Diabetes. Prevalence estimates are therefore derived from Scotland's national registry (where 6% of the population are affected) applied to Ireland's similar population size, suggesting approximately 308,000 people are living with diabetes in Ireland today.

88%
Of cases are Type 2 diabetes
285
New Type 1 diagnoses annually in children under 15
Top 25%
Ireland's Type 1 incidence rate — globally among the highest

Source: HSE National Clinical Programme for Diabetes; Diabetes Ireland prevalence data; Irish Longitudinal Study on Ageing (TILDA).

Research published in July 2025 by RCSI University of Medicine and Health Sciences — analysing Healthy Ireland survey data from 2015 to 2023 — found striking inequalities: those from disadvantaged communities were almost three times more likely to have diabetes (6%) compared to those from more affluent areas (2.2%). This underscores that diabetes in Ireland is not only a health challenge, but a social one.

Are you at risk and don't know it? It is estimated that a significant proportion of people with Type 2 diabetes in Ireland are undiagnosed. If you have risk factors — a family history of diabetes, excess weight around the abdomen, high blood pressure, or a sedentary lifestyle — speak to your GP about a fasting blood glucose or HbA1c test.

Section 02

Types of Diabetes

Not all diabetes is the same. Understanding the type you have — or are at risk of — is the first step to effective management.

Type 1 Diabetes
Autoimmune · Insulin-dependent
The immune system destroys insulin-producing beta cells in the pancreas. The body produces little or no insulin. Requires lifelong insulin therapy. Typically develops in childhood or young adulthood, though it can occur at any age. Accounts for approximately 10–12% of cases in Ireland.
Type 2 Diabetes
Lifestyle & genetic · Progressive
The body becomes resistant to insulin or does not produce enough. Strongly linked to lifestyle factors. By far the most common form — approximately 88% of cases in Ireland. Can often be managed initially with diet, exercise and oral medication, though many patients eventually require insulin.
Gestational Diabetes
Pregnancy-related · Usually temporary
Develops during pregnancy when hormonal changes impair insulin function. Usually resolves after delivery but significantly increases lifetime risk of Type 2 diabetes for both mother and child. Screened for routinely in Irish maternity services between weeks 24–28.
Prediabetes
Preventable · Often reversible
Blood glucose is higher than normal but not yet at diabetic levels. A critical intervention window — lifestyle changes at this stage can prevent or significantly delay the onset of full Type 2 diabetes. Many people in Ireland are in this category without knowing it.

Section 03

Causes and Risk Factors

Type 1 Diabetes

The exact cause of Type 1 diabetes remains incompletely understood. It is an autoimmune condition — the body's immune system incorrectly targets and destroys the beta cells of the pancreas, which are responsible for producing insulin. Genetic factors play a role, as does potentially exposure to certain viral infections during development. Ireland has one of the highest rates of childhood Type 1 diabetes in the world, a pattern that has been studied by researchers at institutions including University College Dublin and Trinity College Dublin, though the reasons for Ireland's elevated incidence remain the subject of active research.

Type 2 Diabetes

Type 2 diabetes has a more complex and modifiable set of causes, combining genetic predisposition with lifestyle and environmental factors. The core mechanism is insulin resistance — where the body's cells stop responding effectively to insulin — combined with a progressive decline in the pancreas's ability to compensate by producing more.

Excess body weightParticularly abdominal (visceral) fat. Obesity is the single strongest modifiable risk factor for Type 2 diabetes.
Physical inactivitySedentary behaviour reduces insulin sensitivity. Regular movement is one of the most effective preventive and management tools.
Diet high in processed foodsHigh intake of refined carbohydrates, sugar and ultra-processed foods is strongly associated with insulin resistance.
Family historyHaving a first-degree relative with Type 2 diabetes significantly elevates your personal risk.
Age over 45Risk increases with age. TILDA data show 10% of Irish adults over 50 have Type 2 diabetes, rising to 16% over 80.
High blood pressure or cholesterolMetabolic risk factors often cluster together. Hypertension and dyslipidaemia frequently co-occur with insulin resistance.
Previous gestational diabetesWomen who developed gestational diabetes have a substantially elevated lifetime risk of developing Type 2 diabetes.
EthnicityPeople of South Asian, African-Caribbean and Middle Eastern descent have higher rates of Type 2 diabetes at lower BMI thresholds.

Section 04

Signs and Symptoms

Symptoms vary considerably between Type 1 and Type 2 diabetes. Type 1 often presents acutely — with rapid onset of symptoms that may signal diabetic ketoacidosis (DKA), a medical emergency. Type 2, by contrast, typically develops slowly and silently over years, with symptoms so mild or gradual that many people attribute them to aging, stress or fatigue.

Increased thirstPersistent, unquenchable thirst — polydipsia — as the kidneys work harder to filter excess glucose.
Frequent urinationPolyuria, particularly at night (nocturia). Often the most disruptive early symptom.
FatiguePersistent tiredness even after adequate sleep, caused by cells being deprived of glucose for energy.
Unexplained weight lossParticularly in Type 1 — the body breaks down fat and muscle for energy when insulin is absent.
Blurred visionHigh blood glucose causes fluid shifts in the lens of the eye, temporarily affecting focus.
Slow wound healingImpaired circulation and immune function slow the healing of cuts, sores and infections.
Tingling or numbnessPeripheral neuropathy — affecting hands and feet — can be an early or presenting sign, particularly in Type 2.
Increased hungerPolyphagia — persistent hunger even after eating — occurs when cells cannot absorb glucose effectively.
When to seek urgent care: If you or a family member experiences rapid onset of severe thirst, excessive urination, vomiting, abdominal pain, confusion, or fruity-smelling breath — particularly in a child or young adult — this may indicate diabetic ketoacidosis (DKA), a medical emergency. Call 999 or 112 immediately or go to your nearest Emergency Department.

Section 05

Current Treatments for Diabetes in Ireland

Diabetes treatment has undergone a genuine revolution in the last decade. The HSE National Clinical Programme for Diabetes, with support from the Department of Health, launched updated National Clinical Guidelines for both Type 1 and Type 2 diabetes in May 2024 — reflecting these advances and setting a new standard for care in Ireland.

Lifestyle Modification — The Foundation of All Treatment

For both Type 1 and Type 2 diabetes, lifestyle is the bedrock of management. For Type 2 in particular, dietary change and increased physical activity can significantly reduce HbA1c, improve insulin sensitivity, and in some cases — especially following bariatric surgery or very-low-calorie diets — lead to sustained remission. The HSE's Discover Diabetes programme and structured education initiatives provide evidence-based support for lifestyle management across Ireland.

Pharmacological Treatment

The following are the main drug classes available in Ireland today. Treatment decisions are individualised — the 2024 HSE and American Diabetes Association (ADA) guidelines both emphasise a patient-centred approach that considers cardiovascular risk, kidney function, weight, and personal preference.

Cardiorenal Protection
GLP-1 Receptor Agonists
Semaglutide (Ozempic, Wegovy) · Liraglutide (Victoza)
A transformative class of injectable (and now oral) medications that mimic the gut hormone GLP-1. They lower blood sugar, promote significant weight loss, slow gastric emptying and reduce cardiovascular risk. Now recommended by ADA 2025 guidelines for patients with established cardiovascular disease or high risk. Available in Ireland on prescription.
Cardiorenal Protection
SGLT2 Inhibitors
Empagliflozin (Jardiance) · Dapagliflozin (Forxiga)
These tablets lower blood glucose by causing the kidneys to excrete excess sugar in the urine. Crucially, they also independently protect the heart and kidneys — recommended as first-line for patients with heart failure or chronic kidney disease, regardless of HbA1c. Strong evidence base from landmark trials including EMPA-REG OUTCOME and CREDENCE.
Blood Sugar Control
DPP-4 Inhibitors
Sitagliptin (Januvia) · Linagliptin (Trajenta)
Oral tablets that enhance insulin secretion in a glucose-dependent manner. Weight-neutral, with a low risk of hypoglycaemia. Often used when GLP-1 or SGLT2 agents are not tolerated or appropriate. Available on the GMS scheme in Ireland.
Type 1 & Advanced Type 2
Insulin Therapy
Basal, bolus, pre-mixed insulins · Insulin pumps
Essential for all Type 1 and many Type 2 patients. Modern insulin analogues provide more predictable action profiles than older formulations. Insulin pumps (continuous subcutaneous insulin infusion) offer improved control for selected patients. Available via GP and specialist prescription in Ireland.
Type 1 · New Standard
Continuous Glucose Monitoring (CGM)
Libre · Dexcom · Medtronic
The 2024 HSE National Clinical Guidelines now recommend CGM for all adults with Type 1 diabetes — a landmark change. CGM eliminates the need for finger-prick testing, provides real-time glucose trends and alerts, and improves glycaemic control. The HSE implemented a CGM reimbursement system from December 2023.
2025 ADA Guidelines update: The American Diabetes Association's 2025 guidelines reinforced that GLP-1 receptor agonists and SGLT2 inhibitors should be prioritised for patients with Type 2 diabetes who have established or high-risk cardiovascular disease, heart failure, or chronic kidney disease — independent of HbA1c level. If you have been diagnosed with Type 2 diabetes and have any of these conditions, speak to your doctor about whether these agents are right for you.

Section 06

The Importance of Regular Check-Ups

Diabetes is a chronic condition that changes over time, and its complications — if left undetected — can be serious and irreversible. Diabetic retinopathy is a leading cause of blindness in working-age adults in Ireland. Diabetic nephropathy is a major driver of end-stage kidney disease. Peripheral neuropathy leads to foot complications that in severe cases can result in amputation. Cardiovascular disease risk is significantly elevated in people with diabetes.

The critical insight from decades of research is that all of these complications are largely preventable — or significantly delayed — with good glucose control, blood pressure management, and regular monitoring. The annual structured diabetes review is one of the most evidence-based and cost-effective interventions in all of medicine.

What Your Annual Diabetes Review Should Include

  • HbA1c measurement (your 3-month average blood glucose)
  • Blood pressure measurement and review of antihypertensive therapy
  • Kidney function — eGFR and urine albumin-to-creatinine ratio (ACR)
  • Cholesterol and lipid profile
  • Weight and BMI assessment
  • Foot examination — including assessment of pulses and sensation
  • Retinal screening — annual photography via the Diabetic RetinaScreen programme
  • Medication review and adjustment as needed
  • Review of diabetes self-management education
  • Smoking status assessment and cessation support if applicable
  • Flu vaccination (strongly recommended for people with diabetes)

Screening for Those Not Yet Diagnosed

If you have risk factors for Type 2 diabetes and have never been tested, your GP can arrange a simple fasting blood glucose test or HbA1c blood test. This is especially important if you are over 45, have a family history of diabetes, have high blood pressure, or were overweight during pregnancy. Early detection of prediabetes provides a genuine window of opportunity to prevent or delay the onset of Type 2 diabetes through lifestyle change.

Diabetic RetinaScreen — a free national programme: All people with diabetes in Ireland aged 12 and over are entitled to free annual retinal photography through the Diabetic RetinaScreen programme, run by the HSE. Early detection of retinopathy through this programme has prevented thousands of cases of blindness in Ireland. Make sure you are registered.

Section 07

The Future of Diabetes Treatment

The pace of innovation in diabetes medicine is unprecedented. Several areas of research — some already entering clinical trials — have the potential to fundamentally change what it means to live with diabetes within the next decade.

Phase 1/2/3 Trial · 2026 Submission
Stem Cell-Derived Beta Cell Therapy
Vertex Pharmaceuticals' Zimislecel (formerly VX-880) involves infusing fully differentiated, insulin-producing islet cells derived from stem cells into the hepatic portal vein — aiming to restore endogenous insulin production in Type 1 diabetes. As of June 2025, the pivotal trial has enrolled 50 participants, with regulatory submission expected in 2026. A published review in PMC (2025) describes stem cell therapy as potentially "transformative" by addressing both beta-cell regeneration and immune modulation simultaneously.
Clinical Development
Artificial Pancreas Systems
Closed-loop insulin delivery systems — combining continuous glucose monitors with automated insulin pumps — already represent a major advance for Type 1 patients. Next-generation systems incorporate machine learning algorithms to predict glucose fluctuations before they occur, moving beyond reactive dosing. Several systems are already approved and reimbursed for selected patients in Ireland.
Emerging Therapies
Dual and Triple Receptor Agonists
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has demonstrated superior HbA1c reduction and weight loss compared to existing GLP-1 agents and is now available in Ireland. Triple agonists (GLP-1/GIP/glucagon) are in advanced clinical trials and may offer even greater metabolic benefits.
Immunotherapy Research
Immune Modulation for Type 1
Teplizumab (anti-CD3 monoclonal antibody) has been shown in clinical trials to delay the onset of clinical Type 1 diabetes by a median of approximately two years in high-risk individuals. Research into immune checkpoint inhibitors and tolerance induction continues, with the goal of preserving residual beta-cell function at diagnosis.
Precision Medicine
Genomics and AI-Guided Treatment
Genetic profiling is beginning to identify sub-types of diabetes that respond differently to specific medications. AI-enabled continuous glucose monitors that learn individual metabolic patterns and make personalised recommendations are in development, with potential to transform day-to-day diabetes management.
Regenerative Medicine
Beta-Cell Encapsulation
A parallel strategy to stem cell transplantation involves encapsulating insulin-producing cells within protective biomaterial devices that shield them from immune destruction — potentially eliminating the need for immunosuppression. The Diabetes Research Institute at the University of Miami has demonstrated proof-of-concept in clinical trials, with the first patient achieving insulin independence.

Research into stem cell therapy for Type 1 diabetes is reviewed in detail in a 2025 publication in PMC (PMID: PMC12689004), which concludes that "stem cell therapy offers a two-pronged strategy: regenerating insulin-producing beta cells and regulating immune responses." While a definitive cure remains ahead, the direction of travel is clearer than it has ever been.


Section 08

Key Irish Institutions and Resources

If you are living with diabetes in Ireland, or concerned you may be at risk, the following organisations and services are your primary points of reference for clinical care, education and support.

HSE National Clinical Programme for Diabetes

Established in 2010, the HSE National Clinical Programme for Diabetes provides clinical leadership across all aspects of diabetes care in Ireland. In May 2024 it published landmark updated guidelines for both Type 1 and Type 2 diabetes — the most significant revision in a decade. These guidelines, available on the HSE website, define best practice for primary care and specialist management in Ireland.

Diabetes Ireland

Diabetes Ireland is the national charity for people living with diabetes. It provides education, advocacy, support groups and a comprehensive online resource library. It has consistently called for the establishment of a national diabetes registry and for improved access to newer medications including CGM and GLP-1 agents across the public health system.

Diabetic RetinaScreen

The Diabetic RetinaScreen programme offers free annual retinal photography to all people with diabetes in Ireland aged 12 and over. This population-based screening programme has been instrumental in detecting early retinopathy — when treatment is most effective — and has prevented thousands of cases of preventable blindness in Ireland.


Section 09

Frequently Asked Questions

How many people have diabetes in Ireland?

It is estimated that approximately 308,000 people are living with diabetes in Ireland, with around 272,904 of those having Type 2 diabetes. Ireland does not yet have a national diabetes registry, so these estimates are based on Scottish prevalence data applied to the Irish population by the HSE. Ireland also has one of the highest rates of childhood Type 1 diabetes in the world, with approximately 285 new diagnoses annually in children under 15.

What are the early warning signs of diabetes?

The most common early signs include increased thirst, frequent urination (especially at night), unexplained fatigue, blurred vision, slow healing of cuts or wounds, increased hunger even after eating, and tingling or numbness in the hands or feet. Importantly, Type 2 diabetes can develop slowly and silently — many people have no symptoms for years before diagnosis. If you have risk factors, ask your GP about a fasting blood glucose or HbA1c test even in the absence of symptoms.

What is the difference between Type 1 and Type 2 diabetes?

Type 1 diabetes is an autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas. It requires lifelong insulin therapy and typically presents in childhood or young adulthood. Type 2 diabetes occurs when the body becomes resistant to insulin or does not produce enough — it is strongly associated with lifestyle factors such as diet, physical inactivity and excess weight, and accounts for approximately 88% of all diabetes cases in Ireland. The two conditions have different causes, treatments and clinical courses, though both require careful management to prevent complications.

What are the best current treatments for Type 2 diabetes in Ireland?

Current first-line treatment typically begins with metformin alongside lifestyle modification (dietary change and increased physical activity). Newer drug classes — particularly GLP-1 receptor agonists (such as semaglutide/Ozempic) and SGLT2 inhibitors (such as empagliflozin/Jardiance) — have transformed treatment by not only lowering blood sugar but also protecting the heart and kidneys and aiding weight loss. The 2024 HSE updated Integrated Model of Care for Type 2 Diabetes and the ADA 2025 guidelines both recommend these agents for patients with cardiovascular disease, heart failure or kidney disease. Treatment is individualised — your GP or endocrinologist will tailor your plan to your specific profile.

How often should I get checked if I have diabetes in Ireland?

If you are diagnosed with diabetes, a structured annual review with your GP is recommended as a minimum — covering HbA1c, blood pressure, kidney function, cholesterol, weight, foot examination, and retinal screening via the Diabetic RetinaScreen programme. More frequent HbA1c checks (every 3–6 months) are appropriate if glucose control is not at target or if treatment has been changed. The 2024 HSE guidelines also recommend continuous glucose monitoring (CGM) for all adults with Type 1 diabetes in Ireland.

Can diabetes be cured or put into remission?

Type 2 diabetes can in some cases be put into remission — defined as achieving near-normal blood glucose levels without medication — through significant weight loss, often via very-low-calorie diets or bariatric surgery. The landmark DiRECT trial demonstrated remission in approximately 50% of participants at one year following a structured dietary programme. This does not mean the underlying tendency is eliminated — remission requires sustained lifestyle change to maintain. Type 1 diabetes currently cannot be cured, though promising stem cell therapies in clinical trials aim to restore insulin production and may reach patients within the next several years.

Can I consult a doctor about diabetes online in Ireland?

Yes. Global Health offers online GP consultations with Irish Medical Council-registered doctors from €39 — including diabetes review appointments, assessment of symptoms consistent with diabetes, medication review, and referral for blood tests including HbA1c, fasting glucose and full metabolic panel. Sick leave certificates can be issued where clinically appropriate. For patients in Dublin, clinical-grade home lab test kits (including HbA1c and full metabolic panels) are also available. Book at myglobalhealth.online or email globalhealth@myglobalhealth.online.

Medical Disclaimer Written by Dr Tiago Miguel Figueira (IMC 523449), Clinical Director at Global Health. This article is for general informational and educational purposes only and does not constitute personalised medical advice. Information is based on HSE guidelines, ADA guidelines, Diabetes Ireland publications and peer-reviewed literature current as of June 2026. If you are experiencing symptoms of diabetes or a medical emergency, call 999 or 112 immediately or attend your nearest Emergency Department.

Next step

Ready to speak with a doctor?

Book an online consultation with a locally-registered doctor in your country. Open appointments are shown during booking.

Book consultation

More articles

Diabetes in Ireland: Causes, Symptoms & Treatment 2026